Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis with poor kidney function: a subgroup analysis of the Aspreva Lupus Management Study
- PMID: 23375819
- DOI: 10.1053/j.ajkd.2012.11.042
Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis with poor kidney function: a subgroup analysis of the Aspreva Lupus Management Study
Abstract
Background: Mycophenolate mofetil (MMF) frequently is used as an alternative to intravenous cyclophosphamide to treat lupus nephritis. Whether MMF is adequate for patients with severely decreased kidney function at the time of treatment is uncertain.
Study design: We conducted a post hoc subgroup analysis of patients with low estimated glomerular filtration rates (eGFRs) from a large trial of MMF compared to cyclophosphamide in lupus nephritis.
Settings & participants: We included all patients with an eGFR <30 mL/min/1.73 m(2) from the Aspreva Lupus Management Study (ALMS).
Intervention: MMF (target, 3 g/d) compared to monthly intravenous cyclophosphamide (0.5-1 g/m(2)).
Outcomes: We compared the proportion of patients that responded to therapy and change in eGFR over 24 weeks.
Measurements: Response was evaluated by a decrease in proteinuria and stabilization or improvement of serum creatinine level.
Results: Of 370 patients in ALMS, 32 were included in the subgroup analysis: 20 randomly assigned to MMF and 12 randomly assigned to cyclophosphamide treatment. The patients included were similar at baseline between groups. Four (20.0%) patients treated with MMF responded compared with 2 (16.7%) patients treated with cyclophosphamide (risk ratio, 1.2; 95% CI, 0.3-5.1; P = 0.9). eGFR in the MMF group improved more quickly than in the cyclophosphamide group, by 1.51 (95% CI, 0.99-2.02) mL/min/1.73 m(2) each week (P < 0.001). Serious adverse events occurred in 9 (45.0%) MMF-treated patients and 7 (63.6%) cyclophosphamide-treated patients (P = 0.5).
Limitations: Small sample size and post hoc subgroup of a larger trial.
Conclusions: We did not detect a difference in the primary outcome of response in patients with low eGFR treated with MMF or cyclophosphamide. However, MMF may result in quicker recovery of kidney function compared with those treated with cyclophosphamide. Larger studies including more patients with poor kidney function are warranted.
Copyright © 2013 National Kidney Foundation, Inc. All rights reserved.
Comment in
-
Mycophenolate mofetil in severe lupus nephritis: should post hoc analyses change treatment patterns?Am J Kidney Dis. 2013 May;61(5):692-3. doi: 10.1053/j.ajkd.2013.02.346. Am J Kidney Dis. 2013. PMID: 23582251 No abstract available.
Similar articles
-
Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide.Arthritis Care Res (Hoboken). 2011 Mar;63(3):351-7. doi: 10.1002/acr.20397. Epub 2010 Nov 15. Arthritis Care Res (Hoboken). 2011. PMID: 21080348 Clinical Trial.
-
Low dose mycophenolate mofetil versus cyclophosphamide in the induction therapy of lupus nephritis in Nepalese population: a randomized control trial.BMC Nephrol. 2018 Jul 11;19(1):175. doi: 10.1186/s12882-018-0973-7. BMC Nephrol. 2018. PMID: 29996800 Free PMC article. Clinical Trial.
-
Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide.Lupus. 2007;16(9):707-12. doi: 10.1177/0961203307081340. Lupus. 2007. PMID: 17728363 Clinical Trial.
-
Mycophenolate mofetil in the treatment of systemic lupus erythematosus.Curr Opin Rheumatol. 2011 Sep;23(5):454-8. doi: 10.1097/BOR.0b013e328349a1e5. Curr Opin Rheumatol. 2011. PMID: 21720247 Review.
-
Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials.Nephrol Dial Transplant. 2007 Jul;22(7):1933-42. doi: 10.1093/ndt/gfm066. Epub 2007 Apr 3. Nephrol Dial Transplant. 2007. PMID: 17405792 Review.
Cited by
-
Do we really need cyclophosphamide for lupus nephritis?Pediatr Nephrol. 2024 Apr 12. doi: 10.1007/s00467-024-06367-9. Online ahead of print. Pediatr Nephrol. 2024. PMID: 38607424
-
Severe lupus nephritis in the present days.Front Nephrol. 2022 Aug 24;2:984613. doi: 10.3389/fneph.2022.984613. eCollection 2022. Front Nephrol. 2022. PMID: 37675028 Free PMC article. Review.
-
Diagnosis and treatment of lupus nephritis: a summary of the Consensus Document of the Spanish Group for the Study of Glomerular Diseases (GLOSEN).Clin Kidney J. 2023 Mar 22;16(9):1384-1402. doi: 10.1093/ckj/sfad055. eCollection 2023 Sep. Clin Kidney J. 2023. PMID: 37664575 Free PMC article. Review.
-
Perspectives on Mycophenolate Mofetil in the Management of Autoimmunity.Clin Rev Allergy Immunol. 2023 Aug;65(1):86-100. doi: 10.1007/s12016-023-08963-3. Epub 2023 Jun 20. Clin Rev Allergy Immunol. 2023. PMID: 37338709 Review.
-
Response to therapy at 6 months predicts long-term renal outcome in lupus nephritis with poor kidney function.Lupus Sci Med. 2022 Dec;9(1):e000773. doi: 10.1136/lupus-2022-000773. Lupus Sci Med. 2022. PMID: 36581380 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous